<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02793492</url>
  </required_header>
  <id_info>
    <org_study_id>TIS2015-01</org_study_id>
    <nct_id>NCT02793492</nct_id>
  </id_info>
  <brief_title>Misago® RX Self-expanding Peripheral Stent for Common and/or External Iliac Artery</brief_title>
  <acronym>OSPREY ILIAC</acronym>
  <official_title>OSPREY ILIAC: Occlusive/Stenotic Peripheral Artery REvascularization StudY for Common and/or External ILIAC Artery Using the Misago® RX Self-expanding Peripheral Stent</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Terumo Medical Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Beth Israel Deaconess Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Terumo Medical Corporation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
    <is_ppsd>No</is_ppsd>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multi-center, single arm, non-randomized, prospective clinical study using the
      Misago® RX Self-expanding Peripheral Stent for treatment of de novo, restenotic, and/or
      occlusive lesion(s) of the common and/or external iliac artery.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 2019</start_date>
  <completion_date type="Anticipated">April 2023</completion_date>
  <primary_completion_date type="Anticipated">October 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Freedom from the composite Major Adverse Event rate, defined as periprocedural related death, amputation of the target limb, and clinically driven TLR assessed at 9 months post-procedure.</measure>
    <time_frame>9 months post-procedure</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Major Adverse Event rate at 30 days, and 12, 24, and 36 months post-procedure defined as a composite of peri-procedural related death, amputation of the target limb, and clinically driven TLR.</measure>
    <time_frame>30 days, 12, 24, and 36 months post-procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Primary stent patency at 9 months defined by a binary duplex ultrasound peak systolic velocity ratio ≤ 2.4 at the stented target lesion and absence of TLR.</measure>
    <time_frame>9 months post-procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Technical Success defined by the following conditions: 1) Successful delivery of the stent at the lesion site 2) Stent(s) successfully deployed in lesion with adequate lesion coverage</measure>
    <time_frame>The outcome is assessed up to 24 hours from time of enrollment through index procedure.</time_frame>
    <description>Technical success will be evaluated from time of enrollment through index procedure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Procedural Success: Attainment of &lt; 30% residual stenosis of the target lesion and no peri-procedural complications.</measure>
    <time_frame>The outcome is assessed up to 24 hours from time of enrollment through index procedure</time_frame>
    <description>Procedural success will be evaluated from time of enrollment through index procedure. Peri-procedural complications defined as: death, stroke, myocardial infarction (MI), emergent surgical revascularization, significant distal embolization in target limb, and thrombosis of target vessel.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Success: Relief or improvement (without increase of one or more in the score) from baseline symptoms as measured by the Rutherford score for chronic limb ischemia at 30 days as compared to baseline.</measure>
    <time_frame>30 days post-procedure</time_frame>
    <description>Clinical success will be evaluated from time of enrollment through index procedure. In addition, evaluation of Rutherford sustained (without increase of one or more in the score) at 9 months post-procedure from 30 days post-procedure for durability of results.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ankle Brachial Index (ABI) change from baseline</measure>
    <time_frame>through 9 months post-procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinically driven Target Vessel Revascularization (TVR) at 30 days and 9, 12, 24, and 36 months post-procedure</measure>
    <time_frame>30 days and 9, 12, 24, and 36 months post-procedure</time_frame>
    <description>TVR is defined as any re-intervention or artery bypass surgery involving the target vessel in which the subject has ≥ 50% diameter stenosis with worsening symptoms, or ≥ 70% stenosis without symptoms. The target vessel is defined as the vessel containing the treated lesion (e.g., common and/or external iliac artery).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinically driven TLR through 30 days and 9, 12, 24, and 36 months post-procedure.</measure>
    <time_frame>30 days and 9, 12, 24, and 36 months post-procedure</time_frame>
    <description>Clinically driven TLR is defined as re-intervention of the target lesion in which subject has ≥ 50% stenosis with worsening symptoms, or ≥ 70% stenosis without symptoms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Walking Impairment Questionnaire</measure>
    <time_frame>through 9 months post-procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of all AEs</measure>
    <time_frame>pre-discharge through 36 months post-procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of access site complications including severe bleeding, hematoma, and pseudoaneurysm, occurring prior to hospital discharge.</measure>
    <time_frame>The event is assessed from time of enrollment through hospital discharge or up to 7 days post procedure, whichever occurs first</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of device failure through the 36 months post-procedure.</measure>
    <time_frame>through 36 months post-procedure</time_frame>
    <description>Device failure is defined as use of the device in accordance with the IFU, but does not perform as described in the IFU, and also negatively impacts treatment of the study subject.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Device Related Complications</measure>
    <time_frame>9 months post-procedure</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">101</enrollment>
  <condition>Iliac Artery Stenosis</condition>
  <arm_group>
    <arm_group_label>Misago® RX Self-expanding Stent</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eligible participants will undergo stent implantation with the Misago® RX Self-expanding Stent</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Misago® RX Self-expanding Peripheral Stent</intervention_name>
    <description>the Misago® RX Self-expanding Stent is a bare metal, nitinol stent</description>
    <arm_group_label>Misago® RX Self-expanding Stent</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Baseline:

          1. Is ≥ 18 years old and of legal consent.

          2. Is willing to comply with all follow-up evaluations at the specified times.

          3. Subject or subject's legal representative has been informed of and understands the
             nature of the study and provides signed informed consent to participate in the study.

          4. Has a Rutherford Clinical Category Score of 2, 3 or 4 (index limb only).

          5. Resting ABI of &lt; 0.9, or abnormal exercise ABI.

             Intra-procedure:

          6. De novo, restenotic, and/or occlusive target lesion(s) located within the native
             common and/or external iliac artery: proximal point at or distal to the ostium of the
             common iliac artery and distal point at least 1 cm above the Inferior Epigastric
             Artery (IEA) as measured by straight anteroposterior (AP) view.

          7. Radiographic evidence of ≥ 50% stenosis or restenosis (from PTA or adjunct therapy,
             not including stents or stent grafts), or occlusion of target lesion(s) in the common
             iliac artery and/or external iliac artery.

          8. Total combined length of lesion(s) is ≤ 120 mm as determined by the investigator and
             is amenable to stenting.

          9. Reference vessel diameter is ≥ 4.0 mm and ≤ 9.0 mm.

         10. Radiographic evidence in the target limb of straight line femoropopliteal flow, either
             not requiring CFA/SFA/popliteal treatment for significant stenosis (≥ 50% stenosis or
             occlusion, as confirmed by angiography during the index procedure), OR has undergone
             successful treatment according to protocol specifications with &lt; 30% residual stenosis
             and no procedural complications prior to enrollment in the study.

         11. At least one patent infrapopliteal artery to the ankle not requiring intervention
             (i.e., &lt; 50% stenosis).

        Exclusion Criteria:

          1. Has had previous stent or stent-graft implantation in the target lesion(s).

          2. Has a contraindication or known untreatable allergy to antiplatelet therapy,
             anticoagulants, thrombolytic drugs or any other drug used during the study according
             to the protocol.

          3. Has known hypersensitivity to contrast material that cannot be adequately pretreated.

          4. Has known hypersensitivity to nickel-titanium (nitinol).

          5. In the opinion of investigator, has bleeding diathesis, coagulopathy, and/or known
             hypercoagulable condition making the patient unsuitable for study participation.

          6. Refuses blood transfusion.

          7. Is female currently breastfeeding, pregnant, or of childbearing potential not using
             adequate contraceptives measures or refuses to use contraception throughout the
             duration of the study.

          8. Has life expectancy of less than 1 year.

          9. Has planned use of thrombectomy, atherectomy, brachytherapy, cryotherapy or laser
             devices to treat the common and/or external iliac arteries during the index procedure.

         10. Has any planned surgical intervention (requiring in-patient hospitalization) 14 days
             before or 30 days after the index procedure.

         11. Is currently participating in an investigational drug or other device study that has
             not yet reached the primary endpoint analysis.

         12. Has known aortic disease requiring intervention within 9 months post index procedure.

         13. In the opinion of the investigator, has one or more of the following co-morbid
             conditions that may impact the subjects safety and/or participation in the study:

               -  History of severe liver disease (i.e. ascites, esophageal varices, liver
                  transplant)

               -  Known or suspected active systemic infection or infection within the target limb

               -  Undergoing immunosuppressant therapy following organ transplant

               -  Chronic Kidney Disease Stage IIIB or worse (i.e., GFR &lt; 45 mL/min)

               -  New York Heart Association Classification of III or IV with hospitalization for
                  decompensated heart failure within 30 days of index procedure

               -  Recent (within 30 days of index procedure) myocardial infarction

               -  Recent (within 30 days of index procedure) hemorrhagic or ischemic stroke

               -  Acute thrombophlebitis or deep venous thrombosis in the index limb to be treated

               -  Any other co-morbid condition that in the judgment of the investigator precludes
                  safe percutaneous intervention

         14. Guide wire cannot successfully cross the target lesion(s) and re-enter true vessel
             lumen beyond the lesion(s), and study device cannot be deployed so that its proximal
             and distal ends will be within the true vessel lumen.*

         15. Aneurysmal target vessel.*

         16. Presence of an acute intraluminal thrombus of the proposed lesion site(s).*

         17. If treatment is required of a non-target lesion distal to the target vessel during the
             index procedure, the non-target lesion must be successfully treated (residual stenosis
             &lt; 30% and no procedural complications) prior to treatment of the target lesion and:

               -  Be located within the native CFA/SFA/PPA

               -  The distal point must be at least 1 cm above the first branch of the tibial
                  trifurcation

         18. Lack of straight-line blood flow to the foot/ankle of the target limb prior to index
             procedure or inability to achieve straight-line blood flow to the foot/ankle of the
             target limb through treatment of a non-target lesion in the CFA/SFA/proximal popliteal
             during index procedure prior to enrollment.*

         19. Perforation, flow-limiting dissection, or other injury requiring additional stenting
             or surgical intervention prior to the start of target lesion treatment.*
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John Rundback, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Holy Name Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Robert Gash</last_name>
    <phone>1-800-283-7866</phone>
    <phone_ext>4931</phone_ext>
    <email>robert.gash@terumomedical.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Debbie Jackson</last_name>
    <phone>1-800-283-7866</phone>
    <phone_ext>7025</phone_ext>
    <email>debbie.jackson@terumomedical.com</email>
  </overall_contact_backup>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 16, 2016</study_first_submitted>
  <study_first_submitted_qc>June 3, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 8, 2016</study_first_posted>
  <last_update_submitted>October 17, 2017</last_update_submitted>
  <last_update_submitted_qc>October 17, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 19, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

